

**Listing of Claims:**

This listing of the claims will replace all prior versions, and listings, of claims in this Application.

1-105. (Canceled)

106. (Currently amended) A method for transporting a non-steroidal anti-inflammatory drug through human or animal skin or mucous membranes, comprising administering to the skin or a mucous membrane of a human or an animal a vesicular composition comprising:

(a) a vesicle consisting essentially of:

- i) one or more phosphatidyl cholines;
- ii) a salt of one or more non-steroidal anti-inflammatory drugs; and
- iii) one or more stabilizers of phenol, cresol or benzyl alcohol,

wherein an aqueous medium is contained within the vesicle; and

(b) the aqueous medium.

107. (Currently amended) The method composition of claim 106, wherein the aqueous medium is a buffer.

108. (Currently amended) The method composition of claim 107, wherein the buffer has a pH of 3 to 12.

109. (Currently amended) The method composition of claim 108, wherein the buffer has a pH of 5 to 9.

110. (Currently amended) The method composition of claim 109, wherein the buffer has a pH of 6 to 8.

111. (Canceled)

112. (Previously presented) The method of claim 106, wherein at least one of the one or more phosphatidyl cholines is a natural phosphatidyl choline.

113. (Previously presented) The method of claim 112, wherein at least one of the one or more phosphatidyl cholines is from egg, soybean, coconut, olive, saffron, sunflower, linseed, whale fat, primrose, or primula.

114. (Previously presented) The method of claim 106, wherein at least one of the one or more phosphatidyl cholines is a synthetic phosphatidyl choline.

115. (Previously presented) The method of claim 106, wherein at least one of the one or more non-steroidal anti-inflammatory drugs is diclofenac or ibuprofen,

116. (Previously presented) The method of claim 106, wherein the vesicle further consists essentially of one or more consistency modifiers and/or one or more, an antioxidants.

117. (Previously presented) The method of claim 116, wherein the consistency modifier is a hydrogel.

118. (Previously presented) The method of claim 116, wherein the antioxidant is probucol, tocopherol, BHT, ascorbic acid, or desferroxamine.

119. (Canceled)

120. (Currently amended) The method of claim 106, wherein up to 50 mg of the vesicle vesicular composition are administered per  $\text{cm}^2$  of skin surface.

121. (Previously presented) The method of claim 106, wherein the salt is a lithium, sodium, potassium, cesium, rubidium, ammonium, monomethyl, dimethyl, trimethylammonium or ethylammonium salt.